| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H30ClFN2O |
| Molecular Weight | 452.991 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N(C)C(=O)CC1(CCN(C)CC1)C2=CC=C(F)C=C2)C3=C4C=CC=CC4=CC(Cl)=C3
InChI
InChIKey=DRXBWLBZWAJIEF-IBGZPJMESA-N
InChI=1S/C27H30ClFN2O/c1-19(25-17-22(28)16-20-6-4-5-7-24(20)25)31(3)26(32)18-27(12-14-30(2)15-13-27)21-8-10-23(29)11-9-21/h4-11,16-17,19H,12-15,18H2,1-3H3/t19-/m0/s1
| Molecular Formula | C27H30ClFN2O |
| Molecular Weight | 452.991 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
GlaxoSmithKline was developing GSK-424887as a dual antagonist of the human neurokinin receptor 1 and inhibitor of the serotonin transporter. GSK 424887 participated in phase I clinical trials for the treatment of depressive disorder and anxiety disorder. However, further development of GSK 424887 apparently was discontinued.